Literature DB >> 13230514

VARIOUS combinations of isoniazid with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; seventh report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.

.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID ISOMERS/therapeutic use; PARA-AMINOSALICYLIC ACID/therapeutic use; STREPTOMYCIN/therapeutic use; TUBERCULOSIS, PULMONARY/therapy

Mesh:

Substances:

Year:  1955        PMID: 13230514      PMCID: PMC2061210     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  10 in total

1.  Isoniazid and P. A. S. in chronic pulmonary tuberculosis: a warning.

Authors:  C L JOINER; K S MACLEAN; J D CARROLL; K MARSH; P COLLARD; R KNOX
Journal:  Lancet       Date:  1954-10-02       Impact factor: 79.321

2.  Streptomycin reactions: their characteristic features, incidence, etiology and means of prevention.

Authors:  H R RICHES
Journal:  Br J Tuberc Dis Chest       Date:  1954-10

3.  United States Public Health service cooperative investigation of antimicrobial therapy of tuberculosis, V. Report on thirty-two-week observations on combinations of isoniazid, streptomycin, and para-aminosalicylic acid.

Authors:  F W MOUNT; S H FEREBEE
Journal:  Am Rev Tuberc       Date:  1954-09

4.  Infection with drug-resistant tubercle bacilli.

Authors:  O F THOMAS; W M BORTHWICK; N W HORNE; J W CROFTON
Journal:  Lancet       Date:  1954-06-26       Impact factor: 79.321

5.  Isonicotinic acid hydrazide in pulmonary tuberculosis.

Authors:  R M FORD
Journal:  Med J Aust       Date:  1953-09-05       Impact factor: 7.738

6.  Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin; para-aminosalicylic acid in pulmonary tuberculosis therapy. IV. Report on forty-week observations on 583 patients with streptomycin susceptible infections.

Authors:  F W MOUNT; B E JENKINS; S H FEREBEE
Journal:  Am Rev Tuberc       Date:  1953-08

7.  Isoniazid and streptomycin in the treatment of pulmonary tuberculosis.

Authors:  F W PITTS; C W TEMPEL; F L MILLER; J H SANDS; M J FITZPATRICK; O WEISER
Journal:  J Am Med Assoc       Date:  1953-07-04

8.  Therapy of pulmonary tuberculosis with isoniazid alone and in combination with streptomycin and with para-amino-salicylic acid.

Authors:  M THOREN; H C HINSHAW
Journal:  Stanford Med Bull       Date:  1952-11

9.  [Treatment of 414 cases of pulmonary tuberculosis with isoniazid].

Authors:  A LOTTE; J POUSSIER
Journal:  Rev Tuberc       Date:  1953

10.  Intermittent dosage in the treatment of pulmonary tuberculosis with streptomycin; a report to the Streptomycin in Tuberculosis Committee of the Medical Research Council.

Authors:  J R BEGNALL; J W CLEGG; J W CROFTON; B J D SMITH; H D HOLT; D A MITCHISON; P ARMITAGE
Journal:  Br Med J       Date:  1950-05-27
  10 in total
  9 in total

Review 1.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

2.  [Reasons for failures of chemotherapy in tuberculosis].

Authors:  H Sighart
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1968

Review 3.  The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis.

Authors:  Catherine Vilchèze; William R Jacobs
Journal:  J Mol Biol       Date:  2019-02-21       Impact factor: 5.469

4.  Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.

Authors:  Anneke C Hesseling; Paolo Denti; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Maxwell Chirehwa; Jana L Winckler; Jun Mao; Heather R Draper; Lubbe Wiesner; Jennifer Norman; Helen McIlleron; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2022-05-04       Impact factor: 5.938

Review 5.  Antimicrobial Treatment Duration in Sepsis and Serious Infections.

Authors:  Lindsay M Busch; Sameer S Kadri
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

6.  The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line.

Authors:  J Crofton
Journal:  J R Soc Med       Date:  2006-10       Impact factor: 18.000

Review 7.  Multicomponent crystals of anti-tuberculosis drugs: a mini-review.

Authors:  Eustina Batisai
Journal:  RSC Adv       Date:  2020-10-07       Impact factor: 4.036

8.  Emil "Tom" Frei III, MD (1924-2013).

Authors:  Chinmoy K Bose
Journal:  Indian J Med Paediatr Oncol       Date:  2014-01

9.  Utility of para-aminosalicylic acid in drug-resistant tuberculosis: Should it be classified as Group D3 or Group C?

Authors:  Unnati Desai; Jyotsna M Joshi
Journal:  Lung India       Date:  2018 Nov-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.